Search Results

You are looking at 1 - 5 of 5 items for

  • Author or Editor: Joel Topf x
  • Refine by Content Type: All x
Clear All Modify Search
Joel Topf

When Kidney Disease: Improving Global Outcomes (KDIGO) was first announced in 2004, I was confused. We had Kidney Disease Outcomes Quality Initiative (KDOQI), which seemed reasonably successful and had been well integrated into nephrology. I had learned and was teaching the KDOQI chronic kidney disease (CKD) stages. Researchers were using the CKD stages to define populations and create prognostic models. Dialysis providers were adopting the renal osteodystrophy guidelines as treatment targets and directing their nurses, dietitians, and social workers to empower patients to achieve these goals. Additional guidelines seemed superfluous. When I looked into KDIGO, however, I saw something very

Edgar Lerma and Joel Topf

Joel Topf, MD

Kidney News Editorial Board member Edgar Lerma, MD, interviewed Joel Topf, MD, about his experience on the front lines of the COVID-19 pandemic. Topf is a private practice nephrologist who works primarily at St. John Ascension in Detroit. He is also on the faculty of the St. John Nephrology Fellowship program, where he teaches residents and medical students, using his academic energy to engage them through social media. He is co-creator of NephJC and NephMadness and hosts a nephrology-focused podcast called Freely Filtered.

<italic>How did you get to be on the COVID-19 front lines? Did you</italic>
Dominique Tomacruz, Sayna Norouzi, and Joel M. Topf

Hello! Welcome to The Skeleton Key Group (SKG) world. We love analyzing and dissecting electrolyte abnormalities. We publish an electrolyte case every month on the Renal Fellow Network. We are honored to be invited to participate in this special Kidney News issue as part of a series on free open-access medical education (FOAMed).

The stem

A 42-year-old woman with a history of hypertension and diabetes mellitus was evaluated for hypokalemia and hypomagnesemia. She was diagnosed with invasive squamous cell carcinoma of the cervix for which she underwent radical hysterectomy and bilateral pelvic lymph node dissection, external beam radiotherapy

Brendon L. Neuen, Edgar V. Lerma, and Joel Topf

Our top area to watch for 2019 is the advent of sodium glucose cotransporter 2 (SGLT2) inhibitors, oral anti-hyperglycemic agents that have been recently approved for the treatment of type 2 diabetes mellitus (T2DM).

Aside from their glucose-lowering effect, SGLT2 inhibitors have also been shown to reduce blood pressure, body weight, and albuminuria. These multiple beneficial metabolic effects have contributed, at least in part, to reductions in cardiovascular and renal outcomes observed in large cardiovascular outcome trials. As a result, the American Diabetes Association’s 2019 Standards of Medical Care in Diabetes (1) now recommends SGLT2 inhibitors as second-line

Joel Topf, Anna Burgner, Timothy Yau, Pascale Khairallah, Samira S. Farouk, and Matthew A. Sparks

The 9th annual NephMadness is a social media and medical education campaign focused on all things kidney. You can participate in NephMadness during the entire month of March, National Kidney Month. NephMadness adopts the single elimination brackets that are a hallmark of the popular March Madness (the college basketball tournament held yearly in the United States), but with a nephrology twist. Instead of basketball teams, the bracket is populated with 32 nephrology concepts from eight different regions. This year’s regions are: Liquid Biopsy, the return of Animal House, COVID-19, ICU Nephrology, Workforce, Anemia, Primary Care, and Artificial Kidney. Each region